US 11,679,137 B2
Vibrio parahaemolyticus bacteriophage Vib-PAP-4 and use thereof in inhibiting proliferation of Vibrio parahaemoliticus bacteria
Seong Jun Yoon, Seoul (KR); Soo Youn Jun, Seoul (KR); An Sung Kwon, Gyeonggi-do (KR); Hyun Min Song, Seoul (KR); Soon Hye Hwang, Gyeonggi-do (KR); and Sang Hyeon Kang, Seoul (KR)
Assigned to Intron Biotechnology, Inc., Gyeonggi-do (KR)
Appl. No. 16/471,051
Filed by Intron Biotechnology, Inc., Gyeonggi-do (KR)
PCT Filed Nov. 29, 2017, PCT No. PCT/KR2017/013765
§ 371(c)(1), (2) Date Jun. 19, 2019,
PCT Pub. No. WO2018/117462, PCT Pub. Date Jun. 28, 2018.
Claims priority of application No. 10-2016-0175223 (KR), filed on Dec. 21, 2016.
Prior Publication US 2019/0328803 A1, Oct. 31, 2019
Int. Cl. A61K 35/76 (2015.01); A23K 10/18 (2016.01); A61P 31/04 (2006.01); C12N 7/00 (2006.01); A61K 9/00 (2006.01)
CPC A61K 35/76 (2013.01) [A23K 10/18 (2016.05); A61K 9/0014 (2013.01); A61K 9/0056 (2013.01); A61P 31/04 (2018.01); C12N 7/00 (2013.01); C12N 2795/10133 (2013.01); C12N 2795/10171 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A composition for blocking a Vibrio parahaemolyticus infection, inhibiting the development of diseases caused by a Vibrio parahaemolyticus infection, suppressing diseases caused by Vibrio parahaemolyticus, or alleviating the pathological condition of the diseases caused by Vibrio parahaemolyticus, comprising:
maltodextrin and 1×104 pfu/g to 1×1015 plaque-forming units per gram (pfu/g) of proliferated and purified Myoviridae bacteriophage Vib-PAP-4, which has an ability to specifically kill Vibrio parahaemolyticus and a genome represented by SEQ ID NO:1, and is deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 13168BP,
wherein the maltodextrin and Myoviridae bacteriophage Vib-PAP-4 are in a dried mixture.